Crossmark Global Holdings Inc. Raises Stock Holdings in Gilead Sciences, Inc. $GILD

Crossmark Global Holdings Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 528,203 shares of the biopharmaceutical company’s stock after acquiring an additional 15,182 shares during the quarter. Gilead Sciences comprises about 0.9% of Crossmark Global Holdings Inc.’s portfolio, making the stock its 13th largest position. Crossmark Global Holdings Inc.’s holdings in Gilead Sciences were worth $58,630,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Corundum Trust Company INC purchased a new position in Gilead Sciences during the 3rd quarter worth approximately $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter valued at $30,000. MTM Investment Management LLC boosted its holdings in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Millstone Evans Group LLC raised its stake in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GILD shares. Needham & Company LLC reiterated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. HSBC increased their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Mizuho upped their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Finally, Barclays started coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target for the company. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $148.22 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a 50-day moving average price of $137.52 and a 200 day moving average price of $125.43. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The stock has a market cap of $184.00 billion, a P/E ratio of 21.89, a PEG ratio of 1.94 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the firm earned $1.90 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is presently 46.68%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 over the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.